Regeneron Acquisition of Oxular Wipes Out Oxular Workforce

Following Regeneron’s acquisition of U.K.-based biotech Oxular, which develops retinal treatments, an undetermined number of Oxular employees are losing their jobs, Fierce Biotech reported Jan. 2. A Regeneron spokesperson told Fierce that no Oxular employees will join the New York–based biotech, although some will provide short-term consulting help with tech transfer and transition work.